Related Experiment Video
Updated: Feb 12, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Combining chloroquine with RAD001 inhibits tumor growth in a NEN mouse model
Shani Avniel-Polak1, Gil Leibowitz1, Victoria Doviner2
1Neuroendocrine Tumor LaboratoryEndocrinology & Metabolism Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Abstract:
Patients with neuroendocrine neoplasms (NENs) often require systemic treatment, which is frequently limited by the emergence of drug resistance. mTOR inhibitors (mTORi), such as RAD001 (everolimus), have been shown to inhibit neoplasm progression. mTORi stimulates autophagy, a degradation pathway that might promote the survival of neoplasm cells that are exposed to anti-cancer therapy. Chloroquine (CQ), a well-known anti-malarial and anti-rheumatic drug, suppresses autophagy. Based on our previous results, we hypothesized that CQ may enhance the anti-tumorigenic effects of mTORi by inhibiting autophagy and we aimed to examine the anti-tumorigenic effect of CQ, alone or in combination with RAD001. We established a NEN subcutaneous xenograft mouse model and evaluated the effect of the drugs on tumor growth, mTOR pathway, autophagy and apoptosis. CQ alone and in combination with RAD001 significantly decreased neoplasm volume. Histopathological analysis revealed that the combination of CQ and RAD001 markedly inhibited mTOR activity and neoplasm cell growth, along with accumulation of autophagosomes and increased apoptosis. In conclusion, CQ enhances the anti-tumorigenic effect of RAD001 in vivo by inhibiting autophagy. Clinical trials addressing the effects of CQ therapy on neoplasm progression in patients with NENs, mainly in those treated with mTORi, are warranted.
Insights
Chloroquine enhances RAD001 (everolimus) efficacy in neuroendocrine neoplasms (NENs) by inhibiting autophagy. This combination therapy reduced tumor growth and increased cancer cell death, suggesting potential for clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Neuroendocrine neoplasms (NENs) treatment is often hindered by drug resistance.
- mTOR inhibitors (mTORi) like RAD001 show anti-neoplasm effects but can stimulate autophagy, a survival mechanism for cancer cells.
- Chloroquine (CQ) inhibits autophagy, offering a potential strategy to overcome resistance.
Purpose of the Study:
- To investigate the anti-tumorigenic effects of chloroquine (CQ), alone and in combination with RAD001 (everolimus).
- To determine if CQ enhances RAD001 efficacy by inhibiting autophagy in a neuroendocrine neoplasm (NEN) model.
Main Methods:
- A subcutaneous xenograft mouse model of NEN was established.
- Tumor growth, mTOR pathway activity, autophagy markers, and apoptosis were evaluated after treatment with CQ, RAD001, or combination therapy.
- Histopathological analysis was performed.
Main Results:
- Both CQ and RAD001 significantly reduced NEN tumor volume.
- The combination of CQ and RAD001 demonstrated enhanced anti-tumorigenic effects.
- Combined treatment markedly inhibited mTOR activity, suppressed neoplasm cell growth, increased autophagosome accumulation, and promoted apoptosis.
Conclusions:
- Chloroquine (CQ) potentiates the anti-tumorigenic effects of RAD001 (everolimus) in neuroendocrine neoplasms (NENs) by inhibiting autophagy.
- The combination therapy warrants further investigation in clinical trials for NEN patients, particularly those treated with mTOR inhibitors.
Related Concept Videos
Feedback Inhibition
Growth Models with Integration: Problem Solving
Exponential Equations for Modeling Growth
Enzyme Inhibition
Population Growth
Primary and Secondary Growth in Roots and Shoots

